Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
暂无分享,去创建一个
David V Glidden | Kenneth H Mayer | Mauro Schechter | Lorena Vargas | K Rivet Amico | Robert M Grant | D. Glidden | S. Buchbinder | R. Grant | P. Defechereux | L. Bekker | K. Mayer | D. Burns | K. Mulligan | K. Amico | M. Schechter | V. Veloso | J. Rooney | S. Chariyalertsak | J. Lama | P. Goicochea | P. Anderson | E. Kallás | Jia-Hua Zheng | Lane R. Bushman | Peter L Anderson | M. Casapia | Javier R Lama | Vanessa McMahan | Albert Y Liu | Pedro Goicochea | Martín Casapía | Juan Vicente Guanira-Carranza | Maria E Ramirez-Cardich | Orlando Montoya-Herrera | Telmo Fernández | Valdilea G Veloso | Susan P Buchbinder | Suwat Chariyalertsak | Linda-Gail Bekker | Esper Georges Kallás | Kathleen Mulligan | Lane R Bushman | Robert J Hance | Carmela Ganoza | Patricia Defechereux | Brian Postle | Furong Wang | J Jeff McConnell | Jeanny Lee | James F Rooney | Howard S Jaffe | Ana I Martinez | David N Burns | Carmela Ganoza | Jia-Hua Zheng | L. Bushman | V. McMahan | Furong Wang | H. Jaffe | Brian S. Postle | M. E. Ramírez-Cardich | R. Hance | Jean C. Lee | J. J. McConnell | Ana Martínez | T. Fernández | A. Liu | Lorena Vargas | Orlando Montoya-Herrera | María E Ramírez-Cardich | J. V. Guanira-Carranza | Robert J. Hance
[1] Lisa D. Norman,et al. Preparing for the Unexpected , 2016 .
[2] D. Operario,et al. High Acceptability of HIV Pre-exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya , 2013, AIDS and Behavior.
[3] B. Mustanski,et al. Perceived Likelihood of Using HIV Pre-exposure Prophylaxis Medications Among Young Men Who Have Sex with Men , 2013, AIDS and Behavior.
[4] J. Wit,et al. HIV-Negative and HIV-Positive Gay Men’s Attitudes to Medicines, HIV Treatments and Antiretroviral-based Prevention , 2013, AIDS and Behavior.
[5] G. Harper,et al. Sexual Risk Behavior and Risk Reduction Beliefs Among HIV-Positive Young Men Who have Sex with Men , 2013, AIDS and Behavior.
[6] G. Prestage,et al. “It’s Hard to Know What is a Risky or not a Risky Decision”: Gay Men’s Beliefs About Risk During Sex , 2013, AIDS and Behavior.
[7] G. Wagner,et al. Fertility Desires Among HIV-Infected Men and Women in Los Angeles County: Client Needs and Provider Perspectives , 2013, Maternal and Child Health Journal.
[8] P. Sullivan,et al. Assessing Priorities for Combination HIV Prevention Research for Men Who have Sex with Men (MSM) in Africa , 2013, AIDS and Behavior.
[9] W. Mcfarland,et al. Prevalence and Predictors of Conscious Risk Behavior Among San Franciscan Men who have Sex with Men , 2013, AIDS and Behavior.
[10] A. Landay,et al. HIV: So Near and Yet So Far , 2013, Current HIV/AIDS Reports.
[11] R. Crosby. State of Condom Use in HIV Prevention Science and Practice , 2013, Current HIV/AIDS Reports.
[12] A. Minnis,et al. Methodological Lessons from Clinical Trials and the Future of Microbicide Research , 2013, Current HIV/AIDS Reports.
[13] J. Baeten,et al. Correlation Between Pill Counts and Biologic Effects in an HIV-1 Prevention Clinical Trial: Implications for Measuring Adherence , 2013, AIDS and Behavior.
[14] B. Friedland,et al. Characteristics of Female Sex Workers in Southern India Willing and Unwilling to Participate in a Placebo Gel Trial , 2013, AIDS and Behavior.
[15] P. Gorbach,et al. Effect of Computer-Assisted Interviewing on Self-Reported Sexual Behavior Data in a Microbicide Clinical Trial , 2013, AIDS and Behavior.
[16] C. Godfrey,et al. NRTI Backbone in HIV Treatment , 2012, Drugs.
[17] A. Gettie,et al. Characterization of Peripheral and Mucosal Immune Responses In Rhesus Macaques on Long-Term Tenofovir and Emtricitabine Combination Antiretroviral Therapy , 2012, Journal of acquired immune deficiency syndromes.
[18] J. Simoni,et al. State of The Science of Adherence in Pre-Exposure Prophylaxis and Microbicide Trials , 2012, Journal of acquired immune deficiency syndromes.
[19] G. Robbins,et al. Intimacy and sexual decision making: exploring the perspective of HIV positive women over 50. , 2012, AIDS patient care and STDs.
[20] Wayne T. Steward,et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation , 2012, Implementation Science.
[21] Jerome H. Kim,et al. Two unique recombinant forms identified in incident HIV type 1 infections in Thai blood donors. , 2012, AIDS research and human retroviruses.
[22] C. Beyrer,et al. Associations of consistent condom use among men who have sex with men in Abuja, Nigeria. , 2012, AIDS research and human retroviruses.
[23] A. Carballo-Diéguez,et al. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. , 2012, AIDS research and human retroviruses.
[24] L. Bélec,et al. Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides. , 2012, AIDS research and human retroviruses.
[25] A. Gettie,et al. The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. , 2012, AIDS research and human retroviruses.
[26] E. Roberts,et al. HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. , 2012, Social science & medicine.
[27] C. Dezzutti,et al. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. , 2012, Antiviral research.
[28] C. Beyrer,et al. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs , 2012, Current opinion in HIV and AIDS.
[29] P. Bonnard,et al. PreP un nouvel outil de prévention contre le VIH , 2012 .
[30] M. Hernán,et al. Reply to ‘Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial’ , 2012 .
[31] W. Heneine,et al. Animal models of antiretroviral prophylaxis for HIV prevention , 2012, Current opinion in HIV and AIDS.
[32] K. Mayer,et al. Engaging healthcare providers to implement HIV pre-exposure prophylaxis , 2012, Current opinion in HIV and AIDS.
[33] L. Paxton. Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings , 2012, Current opinion in HIV and AIDS.
[34] S. Cu-Uvin,et al. Antiretrovirals and safer conception for HIV-serodiscordant couples , 2012, Current opinion in HIV and AIDS.
[35] A. Tsai. A typology of structural approaches to HIV prevention: a commentary on Roberts and Matthews. , 2012, Social science & medicine.
[36] I. McGowan. Rectal microbicide development , 2012, Current opinion in HIV and AIDS.
[37] L. Lynen,et al. Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years? , 2012, Expert review of anti-infective therapy.
[38] A. Grulich,et al. Considerations regarding antiretroviral chemoprophylaxis in MSM , 2012, Current opinion in HIV and AIDS.
[39] Ashley A. Eggman,et al. Cost–effectiveness of pre-exposure prophylaxis for HIV: a review , 2012, Current opinion in HIV and AIDS.
[40] P. Saberi,et al. Pharmacists as providers of HIV pre-exposure prophylaxis , 2012, International Journal of Clinical Pharmacy.
[41] Emily M. Lee,et al. Targeting host cofactors to inhibit viral infection , 2012, Frontiers in Biology.
[42] Jean R. Anderson,et al. Preconception and Contraceptive Care for Women Living with HIV , 2012, Infectious diseases in obstetrics and gynecology.
[43] Blair T. Johnson,et al. Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages. , 2012, American journal of public health.
[44] Bin Li,et al. Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. , 2012, Virology.
[45] M. Ryder,et al. Periodontal disease in HIV/AIDS. , 2012, Periodontology 2000.
[46] L. Dandona,et al. Social network and risk-taking behavior most associated with rapid HIV testing, circumcision, and preexposure prophylaxis acceptability among high-risk Indian men. , 2012, AIDS patient care and STDs.
[47] R. Rothenberg,et al. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). , 2012, AIDS education and prevention : official publication of the International Society for AIDS Education.
[48] P. Newman,et al. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand , 2012, Global public health.
[49] J. Denison,et al. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. , 2012, The Cochrane database of systematic reviews.
[50] Peter L. Anderson,et al. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men , 2012, Science Translational Medicine.
[51] R. Steinbrook. Preexposure prophylaxis for HIV infection. , 2012, JAMA.
[52] W. Heneine,et al. Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. , 2012, The Journal of infectious diseases.
[53] J. McIntyre,et al. New HIV prevention technologies and their relevance to MARPS in African epidemics , 2012, SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance.
[54] S. Geibel,et al. A decade of research involving men who have sex with men in sub-Saharan Africa: Current knowledge and future directions , 2012, SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance.
[55] D. Havlir,et al. The beginning of the end of AIDS? , 2012, The New England journal of medicine.
[56] D. Baltimore,et al. As good as it gets? The problem of HIV persistence despite antiretroviral drugs. , 2012, Cell host & microbe.
[57] B. Chi,et al. Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US President's Emergency Plan for AIDS Relief , 2012, Journal of acquired immune deficiency syndromes.
[58] C. Ryan,et al. Prevention of Sexually Transmitted HIV Infections Through the President's Emergency Plan for AIDS Relief: A History of Achievements and Lessons Learned , 2012, Journal of acquired immune deficiency syndromes.
[59] D. Bangsberg,et al. Reproductive Counseling by Clinic Healthcare Workers in Durban, South Africa: Perspectives from HIV-Infected Men and Women Reporting Serodiscordant Partners , 2012, Infectious diseases in obstetrics and gynecology.
[60] A. Abdul-Quader,et al. PEPFAR's Evolving HIV Prevention Approaches for Key Populations—People Who Inject Drugs, Men Who Have Sex With Men, and Sex Workers: Progress, Challenges, and Opportunities , 2012, Journal of acquired immune deficiency syndromes.
[61] Curtis Dolezal,et al. Use of a Rapid HIV Home Test Prevents HIV Exposure in a High Risk Sample of Men Who Have Sex With Men , 2012, AIDS and Behavior.
[62] S. Álvarez,et al. Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[63] Luis I. García,et al. HIV-Negative Seroconcordant Gay Male Couples' Attitudes, Intentions, and Perceived Behavioral Control for Planned Condom Use Within and Outside of Their Relationships , 2012 .
[64] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[65] Thomas J. Smith,et al. An intravaginal ring for the simultaneous delivery of multiple drugs. , 2012, Journal of pharmaceutical sciences.
[66] J. Carey,et al. Development of a Clinical Screening Index Predictive of Incident HIV Infection Among Men Who Have Sex With Men in the United States , 2012, Journal of acquired immune deficiency syndromes.
[67] O. Turriziani,et al. Antiviral therapy: old and current issues. , 2012, International journal of antimicrobial agents.
[68] S. A. Abdool Karim,et al. Overview of microbicides for the prevention of human immunodeficiency virus. , 2012, Best practice & research. Clinical obstetrics & gynaecology.
[69] L. Margolis,et al. Microbicides: still a long road to success. , 2012, Trends in microbiology.
[70] John T Brooks,et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.
[71] L. Baden,et al. Preexposure prophylaxis for HIV--where do we go from here? , 2012, The New England journal of medicine.
[72] W. Cunningham,et al. Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities , 2012, AIDS and Behavior.
[73] C. Beyrer,et al. From personal survival to public health: community leadership by men who have sex with men in the response to HIV , 2012, The Lancet.
[74] Alex Carballo-Diéguez,et al. Successes and challenges of HIV prevention in men who have sex with men , 2012, The Lancet.
[75] P. Sullivan,et al. A call to action for comprehensive HIV services for men who have sex with men , 2012, The Lancet.
[76] A. Nadas,et al. In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines. , 2012, AIDS research and human retroviruses.
[77] B. Sergeyev,et al. Risks for HIV infection among gay, bisexual, and other men who have sex with men in Moscow and St. Petersburg, Russia. , 2012, AIDS research and human retroviruses.
[78] Pai-Lien Chen,et al. Correlation of prospective and cross-sectional measures of HIV type 1 incidence in a higher-risk cohort in Ho Chi Minh City, Vietnam. , 2012, AIDS research and human retroviruses.
[79] P. Halkitis. Obama, marriage equality, and the health of gay men. , 2012, American journal of public health.
[80] J. Mellors,et al. HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[81] Hui Tang,et al. HIV Prevention Interventions to Reduce Racial Disparities in the United States: A Systematic Review , 2012, Journal of General Internal Medicine.
[82] L. Bekker,et al. Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use , 2012, AIDS and Behavior.
[83] K. Buchacz,et al. HIV infection and older Americans: the public health perspective. , 2012, American journal of public health.
[84] O. Uthman,et al. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. , 2012, The Cochrane database of systematic reviews.
[85] N. Michael,et al. Improved outlook on HIV-1 prevention and vaccine development , 2012, Expert opinion on biological therapy.
[86] A. Pettifor,et al. Can Money Prevent the Spread of HIV? A Review of Cash Payments for HIV Prevention , 2012, AIDS and Behavior.
[87] M. Mimiaga,et al. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. , 2012, AIDS patient care and STDs.
[88] E. De Clercq. Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)? , 2012, Medicinal research reviews.
[89] S. Nitayaphan,et al. HIV epidemic in Asia: optimizing and expanding vaccine development , 2012, Expert review of vaccines.
[90] S. Blower,et al. Predicting effect of pre-exposure prophylaxis on HIV epidemics , 2012, The Lancet.
[91] Myron S. Cohen,et al. Pre-exposure prophylaxis for HIV prevention: how to predict success , 2012, The Lancet.
[92] P. Gallay,et al. Sustained Local Delivery of Structurally Diverse HIV-1 Microbicides Released from Sublimation Enthalpy Controlled Matrices , 2012, Pharmaceutical Research.
[93] W. Fischer,et al. Measurements of immune responses for establishing correlates of vaccine protection against HIV. , 2012, AIDS research and human retroviruses.
[94] W. Fisher. “I Think Having the Option Available is a No-Brainer”: Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners? , 2012, Journal of sex research.
[95] A. Giami,et al. Transformations in the Medicalization of Sex: HIV Prevention between Discipline and Biopolitics , 2012, Journal of sex research.
[96] A. Carballo-Diéguez,et al. Will Gay and Bisexually Active Men at High Risk of Infection Use Over-the-Counter Rapid HIV Tests to Screen Sexual Partners? , 2012, Journal of sex research.
[97] G. Nabel,et al. The design and evaluation of HIV-1 vaccines. , 2012, AIDS.
[98] J. Garcia,et al. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. , 2012, Trends in microbiology.
[99] L. Kuhn,et al. Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants? , 2012, AIDS.
[100] G. Vanham,et al. Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine , 2012, Pharmaceutical Research.
[101] F. Hudecz,et al. Synthesis and Cytotoxic Activity of Novel 5-Substituted-1-(β-L-Arabinofuranosyl) Pyrimidine Nucleosides , 2012, Nucleosides, nucleotides & nucleic acids.
[102] Xiaoxu Han,et al. HIV prevention: Bring safe sex to China , 2012, Nature.
[103] J. Shorter,et al. The Surprising Role of Amyloid Fibrils in HIV Infection , 2012, Biology.
[104] L. Bekker,et al. High Acceptability of a Vaginal Ring Intended as a Microbicide Delivery Method for HIV Prevention in African Women , 2012, AIDS and Behavior.
[105] S. A. Abdool Karim,et al. HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials , 2012, AIDS and Behavior.
[106] N. Kapata,et al. Tuberculosis and HIV control in sub-Saharan African prisons: "thinking outside the prison cell". , 2012, The Journal of infectious diseases.
[107] John P. Moore,et al. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission , 2012, Proceedings of the National Academy of Sciences.
[108] W. Heneine,et al. Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis , 2012, Retrovirology.
[109] R. Cone,et al. Evaluation of Microbicide Gel Adherence Monitoring Methods , 2012, Sexually transmitted diseases.
[110] A. Crook,et al. Evaluating the extent of potential resistance to pre‐exposure prophylaxis within the UK HIV‐1‐infectious population of men who have sex with men , 2012, HIV medicine.
[111] L. van Damme,et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention , 2012, AIDS.
[112] Sung-Jae Lee,et al. Demographic and Behavioral Correlates of HIV Risk among Men and Transgender Women Recruited from Gay Entertainment Venues and Community-based Organizations in Thailand: Implications for HIV Prevention , 2012, Prevention Science.
[113] J. Carey,et al. Operational Research to Improve HIV Prevention in the United States , 2012, Journal of acquired immune deficiency syndromes.
[114] J. Baeten,et al. What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples , 2012, Journal of acquired immune deficiency syndromes.
[115] Leila E Mansoor,et al. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection , 2012, Expert opinion on investigational drugs.
[116] M. Carrieri,et al. Acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France , 2012, AIDS care.
[117] M. Mimiaga,et al. Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV: Safety, Tolerability, and Adherence , 2012, Journal of acquired immune deficiency syndromes.
[118] T. Khawcharoenporn,et al. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. , 2012, AIDS patient care and STDs.
[119] E. Clercq,et al. Ten Paths to the Discovery of Antivirally Active Nucleoside and Nucleotide Analogues , 2012, Nucleosides, nucleotides & nucleic acids.
[120] J. Baeten,et al. HIV-1 Prevention for HIV-1 Serodiscordant Couples , 2012, Current HIV/AIDS Reports.
[121] S. A. Abdool Karim,et al. Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies , 2012, AIDS.
[122] P. Cahn,et al. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS , 2012, Expert opinion on investigational drugs.
[123] R. Crosby,et al. Condom use: still a sexual health staple. , 2012, Sexual health.
[124] E. Clercq. Pre-exposure chemoprophylaxis of HIV infection: quo vadis? , 2012, Biochemical pharmacology.
[125] S. Owen. Testing for acute HIV infection: implications for treatment as prevention. , 2012, Current opinion in HIV and AIDS.
[126] Suiyi Tan,et al. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection. , 2012, Fitoterapia.
[127] Charlene A Flash,et al. The Promise of Antiretrovirals for HIV Prevention , 2012, Current Infectious Disease Reports.
[128] R. Paranjape,et al. Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India , 2012, Proceedings of the National Academy of Sciences, India Section B: Biological Sciences.
[129] E. Venables,et al. ‘The study has taught me to be supportive of her’: empowering women and involving men in microbicide research , 2012, Culture, health & sexuality.
[130] K. Mayer,et al. Unprotected Sex, Underestimated Risk, Undiagnosed HIV and Sexually Transmitted Diseases Among Men Who Have Sex With Men Accessing Testing Services in a New England Bathhouse , 2012, Journal of acquired immune deficiency syndromes.
[131] J. Baeten,et al. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence , 2012, Current opinion in infectious diseases.
[132] R. Talwani,et al. HIV in Africa: Challenges and Directions for the Next Decade , 2012, Current Infectious Disease Reports.
[133] V. Stone. HIV/AIDS in Women and Racial/Ethnic Minorities in the U.S. , 2012, Current Infectious Disease Reports.
[134] Sung-Jae Lee,et al. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. , 2012, AIDS patient care and STDs.
[135] J. Kaldor,et al. "Now we are in a different time; various bad diseases have come." understanding men's acceptability of male circumcision for HIV prevention in a moderate prevalence setting , 2012, BMC Public Health.
[136] Marc Lipsitch,et al. Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. , 2012, AIDS.
[137] Peter B Gilbert,et al. Partially Hidden Markov Model for Time-Varying Principal Stratification in HIV Prevention Trials , 2012, Journal of the American Statistical Association.
[138] John P. Moore,et al. Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. , 2012, Virology.
[139] N. Michael. Rare serotype adenoviral vectors for HIV vaccine development. , 2012, The Journal of clinical investigation.
[140] D. Bangsberg,et al. A conceptual framework for understanding HIV risk behavior in the context of supporting fertility goals among HIV-serodiscordant couples , 2012, Reproductive health matters.
[141] R. Valdiserri. Commentary: thirty years of AIDS in America: a story of infinite hope. , 2011, AIDS education and prevention : official publication of the International Society for AIDS Education.
[142] J. Shelton. ARVs as HIV Prevention: A Tough Road to Wide Impact , 2011, Science.
[143] J. Herbst,et al. Differences Between HIV-Positive and HIV-Negative African American Men Who Have Sex with Men in Two Major U.S. Metropolitan Areas , 2011, Archives of Sexual Behavior.
[144] S. Karim,et al. Antiretroviral prophylaxis: a defining moment in HIV control , 2011, The Lancet.
[145] J. Marrazzo,et al. Interventions to prevent sexually transmitted infections, including HIV infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[146] J. McIntyre. Can devices for adult male circumcision help bridge the implementation gap for HIV prevention services? , 2011, Journal of acquired immune deficiency syndromes.
[147] J. Eron,et al. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[148] Myron S. Cohen,et al. Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission , 2011, Science Translational Medicine.
[149] C. Boucher,et al. HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance , 2011, Journal of internal medicine.
[150] J. D. de Wit,et al. Australian Gay Men Who Have Taken Nonoccupational Postexposure Prophylaxis for HIV Are in Need of Effective HIV Prevention Methods , 2011, Journal of acquired immune deficiency syndromes.
[151] J. Levy,et al. HIV/AIDS: 30 Years of progress and future challenges , 2011, European journal of immunology.
[152] Phalguni Gupta,et al. Incorporation of the HIV-1 Microbicide Cyanovirin-N in a Food Product , 2011, Journal of acquired immune deficiency syndromes.
[153] T. Quinn. The 30-year war on AIDS: have we reached the tipping point? , 2011, Sexually transmitted diseases.
[154] S. Vermund,et al. Experience in international clinical research: the HIV Prevention Trials Network. , 2011, Clinical investigation.
[155] Davey M. Smith,et al. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. , 2011, AIDS.
[156] L. McDaid,et al. Willingness to Participate in Future HIV Prevention Studies Among Gay and Bisexual Men in Scotland, UK: A Challenge for Intervention Trials , 2011, AIDS and Behavior.
[157] L. Rohan,et al. The importance of the vaginal delivery route for antiretrovirals in HIV prevention. , 2011, Therapeutic delivery.
[158] P. Volberding. The impact of HIV research on health outcome and healthcare policy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[159] Esther Fearnhill,et al. Transmission Network Parameters Estimated From HIV Sequences for a Nationwide Epidemic , 2011, The Journal of infectious diseases.
[160] B. Mensch,et al. Validation of a Dye Stain Assay for Vaginally Inserted Hydroxyethylcellulose-Filled Microbicide Applicators , 2011, Sexually transmitted diseases.
[161] J. Stover. 30 years after HIV identification: where to from here? , 2011, Expert review of anti-infective therapy.
[162] D. Bangsberg,et al. Reproductive Decision-Making and Periconception Practices Among HIV-Positive Men and Women Attending HIV Services in Durban, South Africa , 2011, AIDS and Behavior.
[163] P. Vernazza,et al. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child , 2011, AIDS.
[164] J. J. van den Oord,et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. , 2011, Cell host & microbe.
[165] V. Soriano,et al. Profilaxis preexposición en la prevención de la infección por virus de la inmunodeficiencia humana , 2011 .
[166] Kenneth H Mayer,et al. Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications , 2011, Current HIV/AIDS reports.
[167] J. Chies,et al. Co‐circulation HIV‐1 subtypes B, C, and CRF31_BC in a drug‐naïve population from Southernmost Brazil: Analysis of primary resistance mutations , 2011, Journal of medical virology.
[168] S. Vermund. Modeling interventions to assess HIV epidemic impact in Africa. , 2011, Journal of acquired immune deficiency syndromes.
[169] Stephen W. Sorensen,et al. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. , 2011, Journal of Acquired Immune Deficiency Syndromes.
[170] J. A. Iribarren,et al. Prevención de la transmisión del VIH (vertical, ocupacional y no ocupacional) , 2011 .
[171] P. Anderson,et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. , 2011, Journal of pharmaceutical and biomedical analysis.
[172] B. Adam. Epistemic fault lines in biomedical and social approaches to HIV prevention , 2011, Journal of the International AIDS Society.
[173] K. MacQueen. Framing the social in biomedical HIV prevention trials: a 20-year retrospective , 2011, Journal of the International AIDS Society.
[174] J. Hakim,et al. HIV prevention in southern Africa: why we must reassess our strategies? , 2011, Tropical medicine & international health : TM & IH.
[175] W. Lewis,et al. Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. , 2011, Fertility and sterility.
[176] M. Rotheram-Borus,et al. A US policy perspective on oral preexposure prophylaxis for HIV. , 2011, American journal of public health.
[177] M. Kieny,et al. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. , 2011, Vaccine.
[178] S. Antimisiaris,et al. Topical nonnucleoside reverse transcriptase inhibitor MC 1220 partially prevents vaginal RT-SHIV infection of macaques. , 2011, AIDS research and human retroviruses.
[179] G. Ramjee. Antiretroviral-based microbicides and oral pre-exposure prophylaxis for HIV prevention , 2011 .
[180] N. Nagelkerke,et al. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study. , 2011, Vaccine.
[181] R. Gray,et al. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. , 2011, Vaccine.
[182] J. Stover,et al. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. , 2011, Vaccine.
[183] C. del Rio,et al. Socioecological influences on community involvement in HIV vaccine research. , 2011, Vaccine.
[184] W. Heneine,et al. Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis , 2011, Journal of acquired immune deficiency syndromes.
[185] M. Perazella,et al. Nephrotoxicity of HAART , 2011, AIDS research and treatment.
[186] S. Hammer. Antiretroviral treatment as prevention. , 2011, The New England journal of medicine.
[187] W. El-Sadr,et al. Game changers: why did the scale-up of HIV treatment work despite weak health systems? , 2011 .
[188] G. J. van den Aardweg. Abuse by Priests, Homosexuality, Humanae vitae, and a Crisis of Masculinity in the Church , 2011, The Linacre quarterly.
[189] G. J. van den Aardweg. On the Psychogenesis of Homosexuality , 2011, The Linacre quarterly.
[190] C. Charpentier,et al. Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. , 2011, Future microbiology.
[191] Q. A. Karim,et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women , 2011, The Lancet.
[192] K. Mayer. Antiretrovirals for HIV prevention: translating promise into praxis , 2011, The Lancet.
[193] I. Susser,et al. Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified? , 2011, The Lancet.
[194] S. Karim,et al. HIV prevention transformed: the new prevention research agenda , 2011, The Lancet.
[195] E. Clercq,et al. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. , 2011, Biochemical pharmacology.
[196] F. Tanser,et al. Targeting strategies and behavior change to combat the HIV epidemic in southern Africa , 2011 .
[197] M. Robb. HIV vaccine development: a new beginning , 2011, Expert review of vaccines.
[198] J. Montaner,et al. Treatment as prevention: preparing the way , 2011, Journal of the International AIDS Society.
[199] A. Harries,et al. The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research , 2011, Journal of the International AIDS Society.
[200] S. Little,et al. MSM: resurgent epidemics , 2011, Current opinion in HIV and AIDS.
[201] S. McCormack,et al. Turning the Tide Against HIV , 2011, Science.
[202] R. Dennin,et al. Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights , 2011, Journal of Zhejiang University SCIENCE B.
[203] A. Kashuba,et al. HIV-1 treatment as prevention: the good, the bad, and the challenges , 2011, Current opinion in HIV and AIDS.
[204] E. Clercq. Acyclic Nucleoside Phosphonates: An Unfinished Story , 2011 .
[205] E. Tolley,et al. Indian married men's interest in microbicide use , 2011, AIDS care.
[206] P. Aggleton,et al. The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches. , 2011, Health education research.
[207] M. Lampe,et al. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. , 2011, American journal of obstetrics and gynecology.
[208] W. Duffus,et al. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. , 2011, AIDS patient care and STDs.
[209] C. Crumpacker,et al. Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. , 2011, Virology.
[210] B. O’Keefe. Anti-HIV microbicide development: targeting the virus is the key , 2011 .
[211] M. Wainberg,et al. Proof of principle: antiretroviral drugs can prevent sexual transmission of HIV-1 , 2011 .
[212] B. Haynes,et al. Acute HIV-1 Infection. , 2011, The New England journal of medicine.
[213] A. Loxley,et al. Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices , 2011, Drug Delivery and Translational Research.
[214] W. Heneine,et al. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques. , 2011, Virology.
[215] B. Herold,et al. HIV Transmission: Time for Translational Studies to Bridge the Gap , 2011, Science Translational Medicine.
[216] E. Dolgin. Trial success spurs planning for rollout of HIV prevention pills , 2011, Nature Medicine.
[217] D. Rey. Post-exposure prophylaxis for HIV infection , 2011, Expert review of anti-infective therapy.
[218] B. Herold,et al. Topical Prophylaxis for HIV Prevention in Women: Becoming a Reality , 2011, Current HIV/AIDS reports.
[219] R. Baggaley,et al. What do mathematical models tell us about the emergence and spread of drug-resistant HIV? , 2011, Current opinion in HIV and AIDS.
[220] G. Vanham,et al. HIV sexual transmission and microbicides , 2011, Reviews in medical virology.
[221] B. Mustanski,et al. HIV in Young Men Who Have Sex with Men: A Review of Epidemiology, Risk and Protective Factors, and Interventions , 2011, Journal of sex research.
[222] K. Mayer,et al. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. , 2011, AIDS patient care and STDs.
[223] M. Wainberg. AIDS: Drugs that prevent HIV infection , 2011, Nature.
[224] Felicity Daly. The introduction of new antiretroviral-based HIV prevention methods into health systems: key issues , 2011, Reproductive health matters.
[225] N. Sewankambo,et al. Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa , 2011, Journal of the International AIDS Society.
[226] N. Michael. Oral preexposure prophylaxis for HIV--another arrow in the quiver? , 2010, The New England journal of medicine.
[227] Lynn Morris,et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.
[228] Connie Celum,et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis , 2010, The Lancet.
[229] Marie-Claude Boily,et al. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention , 2010, International journal of epidemiology.
[230] C. Beyrer,et al. The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. , 2010, Epidemiologic reviews.
[231] Sandra I McCoy,et al. Weighing the gold in the gold standard: challenges in HIV prevention research , 2010, AIDS.
[232] D. Templeton,et al. Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men , 2010, Current opinion in infectious diseases.
[233] W. Heneine,et al. Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection , 2010, Science Translational Medicine.
[234] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[235] D. Watkins,et al. Is an HIV vaccine possible? , 2009, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[236] Y. Marfatia,et al. Pre-exposure prophylaxis in HIV , 2009, Indian journal of sexually transmitted diseases and AIDS.
[237] S. Baral,et al. The global epidemic of HIV infection among men who have sex with men , 2009, Current opinion in HIV and AIDS.
[238] C. Fletcher,et al. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[239] R. Walensky,et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[240] Kenneth H Mayer,et al. Preexposure Antiretroviral Prophylaxis Attitudes in High-Risk Boston Area Men Who Report Having Sex With Men: Limited Knowledge and Experience but Potential for Increased Utilization After Education , 2009, Journal of acquired immune deficiency syndromes.
[241] B. Friedland,et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[242] J. Gallant,et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients , 2008, AIDS.
[243] Lisa M. Lee,et al. Estimation of HIV incidence in the United States. , 2008, JAMA.
[244] H. Teppler,et al. Lack of a Significant Drug Interaction between Raltegravir and Tenofovir , 2008, Antimicrobial Agents and Chemotherapy.
[245] W. Heneine,et al. Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. , 2008, AIDS research and human retroviruses.
[246] M. Mimiaga,et al. Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center , 2008, Journal of acquired immune deficiency syndromes.
[247] Michael Monsour,et al. Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir , 2008, PLoS medicine.
[248] Louis Tong,et al. Limited Knowledge and Use of HIV Post- and Pre-Exposure Prophylaxis Among Gay and Bisexual Men , 2008 .
[249] A. Haase,et al. Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice , 2008, PLoS medicine.
[250] Brian P. Kearney,et al. Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen , 2007, Journal of acquired immune deficiency syndromes.
[251] G. Chittick,et al. Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers , 2007, Journal of clinical pharmacology.
[252] Doug Taylor,et al. Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial , 2007, PLoS clinical trials.
[253] Stephen Moses,et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial , 2007, The Lancet.
[254] Oliver Laeyendecker,et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial , 2007, The Lancet.
[255] C. Fletcher,et al. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[256] J. Kahn,et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[257] Emmanuel Lagarde,et al. Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.
[258] John P. Moore,et al. Promote HIV Chemoprophylaxis Research, Don't Prevent It , 2005, Science.
[259] M. Hochella. The Cost of Science , 2005 .
[260] B. Kearney,et al. Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens , 2005, Journal of acquired immune deficiency syndromes.
[261] S. Lewis. Women and HIV. , 2005, IAPAC monthly.
[262] B. Clotet,et al. Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients , 2005, Antimicrobial Agents and Chemotherapy.
[263] L. Grohskopf,et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[264] F. Rousseau,et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.
[265] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[266] B. Koblin. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study , 2004, The Lancet.
[267] L. Moulton,et al. Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Postexposure Chemoprophylaxis for HIV , 2004, Journal of acquired immune deficiency syndromes.
[268] J. Kahn,et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior , 2004, AIDS.
[269] Christopher Lee Cochran,et al. Human Rights Violations , 2003 .
[270] K. V. Van Rompay,et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. , 2001, The Journal of infectious diseases.
[271] C. Struchiner,et al. Acute Retrovirus Syndrome Among Prospectively Identified Homosexual Men With Incident HIV Infection in Brazil , 2000, Journal of acquired immune deficiency syndromes.
[272] C. Struchiner,et al. Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praça Onze Study Group. , 2000 .
[273] Lawrence Corey,et al. Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.
[274] J. Lambert. Pediatric HIV infection. , 1996, Current opinion in pediatrics.
[275] R. Grant,et al. Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine , 1995, Science.
[276] J. Todd,et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial , 1995, The Lancet.
[277] R. Coleman. Overview of Antiretroviral Therapy , 1994, Pharmacotherapy.
[278] R. Gelber,et al. "Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type I with Zidovudine Treatment." , 1994 .
[279] J. Baeten,et al. Use of hormonal contraceptives and risk of HIV-1 transmission : a prospective cohort study , 2011 .
[280] L. Mandelbrot. Désir d’enfant et VIH : le préservatif est-il dépassé ? , 2012 .
[281] K. V. Van Rompay. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. , 2012, AIDS research and human retroviruses.
[282] E. De Clercq. Human viral diseases: what is next for antiviral drug discovery? , 2012, Current opinion in virology.
[283] J. Montaner,et al. Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime time? , 2012 .
[284] Andreas Meyerhans,et al. HUMAN IMMUNODEFICIENCY VIRUS INFECTION: FROM BIOLOGICAL OBSERVATIONS TO MECHANISTIC MATHEMATICAL MODELLING , 2012 .
[285] D. Cohan,et al. Safer conception options for HIV-serodiscordant couples. , 2012, American journal of obstetrics and gynecology.
[286] J. Stockman,et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men , 2012 .
[287] K. Mayer,et al. Resilience as a Research Framework and as a Cornerstone of Prevention Research for Gay and Bisexual Men: Theory and Evidence , 2012, AIDS and Behavior.
[288] J. Simoni,et al. Oral Adherence Monitoring Using a Breath Test to Supplement Highly Active Antiretroviral Therapy , 2012, AIDS and Behavior.
[289] A. Ziman,et al. Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies. , 2012, Biologicals : journal of the International Association of Biological Standardization.
[290] Matthias Egger,et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. , 2011, The Cochrane database of systematic reviews.
[291] A. Calmy,et al. Le traitement prophylactique de linfection par le virus de limmunodficience humaine (VIH) , 2011 .
[292] S. A. Abdool Karim. Stigma impedes AIDS prevention. , 2011, Nature.
[293] F. van Griensven,et al. ResearchSex frequency and sex planning among men who have sex with men in Bangkok , Thailand : implications for pre-and post-exposure prophylaxis against HIV infection , 2010 .
[294] M. Newman. CHAPTER 42 – Special Issues Regarding Women with HIV Infection , 2008 .
[295] J. Ndinya-Achola. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO.Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.Lancet. 2007 Feb 24;369(9562):643-56. , 2007 .
[296] J. Gallant,et al. Antiretroviral therapy. , 2000, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.
[297] DiClemente Rj,et al. Prevention of human immunodeficiency virus infection among African-American women: sex gender and power and womens risk for HIV. , 1997 .
[298] S. Weir,et al. Prevention of sexual transmission of HIV in sub-Saharan Africa: lessons learned. , 1997, AIDS.
[299] T. W. Allen. Treatment or prevention? , 1988, The Journal of the American Osteopathic Association.